---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014156"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:10:01.093918+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BriaPro subsidiary reports $472K net loss for six months; going concern risk

## Summary
- BriaPro net loss widened to $472,231 for six months ended Jan 31, 2026 vs $233,185 a year ago.
- Accumulated deficit $1.65M; negative working capital $1.64M; cash only $1.
- Going concern: dependent on parent BriaCell for financing; material uncertainty noted.
- On Feb 18, 2026, BriaPro agreed to acquire sCD80 license from BriaCell for cancer therapy.

## SEC filing metadata
- accession: 0001493152-26-014156
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315226014156/0001493152-26-014156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315226014156/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014156
- JSON: https://secwatch.observer/filing/0001493152-26-014156.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.